drugset
Drugs / Glufosfamide
last change Jun 2026 re-read 3 minutes ago

Glufosfamide

also known as beta-D-glucopyranosyl-N,N'-di-(2-chloroethyl)-phosphoric acid diamide · beta-D-glucosylisophosphoramide mustard · D 19575 · Glucosylifosfamide mustard · Glufosfamida

Small molecule

Developed for
malignant pancreatic neoplasm · central nervous system neoplasm · lung cancer · ovarian cancer · pancreatic adenocarcinoma · pancreatic neoplasm · small cell lung carcinoma · soft tissue sarcoma
Investigated by
Threshold Pharmaceuticals · Eleison Pharmaceuticals LLC. · European Organisation for Research and Treatment of Cancer - EORTC · PPD Development, LP

Trials 9

today NCT01954992 · Ph 3 NCT00441467 · Ph 2 NCT00435578 · Ph 2 NCT00442598 · Ph 2 NCT00102752 · Ph 1/2 NCT00099294 · Ph 3 NCT00014300 · Ph 2 NCT00005055 · Ph 2 NCT00005053 · Ph 2
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00102752 Dec 2004 → Jul 2007 pancreatic neoplasm Threshold Pharmaceuticals Completed No outcome recorded
Phase 26 trials
Phase 2 NCT00441467 Mar 2007 → Oct 2008 soft tissue sarcoma Eleison Pharmaceuticals LLC. Completed No outcome recorded
Phase 2 NCT00435578 Feb → Nov 2007 small cell lung carcinoma Threshold Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT00442598 Jan 2007 → Apr 2008 ovarian cancer Eleison Pharmaceuticals LLC. Terminated No outcome recorded
Phase 2 NCT00014300 Jan → Sep 2001 central nervous system neoplasm European Organisation for Research and Treatment of Cancer - EORTC Completed No outcome recorded
Phase 2 NCT00005055 Jan 2000 → Mar 2001 lung cancer European Organisation for Research and Treatment of Cancer - EORTC Completed No outcome recorded
Phase 2 NCT00005053 Dec 1999 → Mar 2001 malignant pancreatic neoplasm European Organisation for Research and Treatment of Cancer - EORTC Completed No outcome recorded
Phase 32 trials
Phase 3 NCT01954992 Apr 2014 → Jun 2026 overdue pancreatic adenocarcinoma Eleison Pharmaceuticals LLC. Recruiting No outcome recorded
Phase 3 NCT00099294 Sep 2004 → Jan 2007 malignant pancreatic neoplasm Threshold Pharmaceuticals Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as glufosfamide ClinicalTrials.gov intervention name — accepted as the source's own label NCT00014300 ↗
8

NCT00099294 ↗

NCT00442598 ↗

NCT01954992 ↗

NCT00005053 ↗

NCT00435578 ↗

NCT00102752 ↗

NCT00005055 ↗

NCT00441467 ↗
Known as beta-D-glucopyranosyl-N,N'-di-(2-chloroethyl)-phosphoric acid diamide “The activity of glufosfamide (beta-D-glucopyranosyl-N,N'-di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II...” PMID 14556925 ↗ Nov 2003
Known as beta-D-glucosylisophosphoramide mustard “The activity of glufosfamide (beta-D-glucosylisophosphoramide mustard) was tested in a multicentre phase II clinical trial in patients with advanced non-small cell lung cancer...” PMID 15010066 ↗ Mar 2004
Known as D 19575 ChEMBL registry synonym — accepted as the source's own label CHEMBL2107143 ↗
Known as Glucosylifosfamide mustard ChEMBL registry synonym — accepted as the source's own label CHEMBL2107143 ↗
Known as Glufosfamida ChEMBL registry synonym — accepted as the source's own label CHEMBL2107143 ↗
Modality Small molecule — CHEMBL2107143 ↗
Route Intravenous “glufosfamide (5 g/m(2)) using a 1-h intravenous (i.v.) infusion every 3 weeks” PMID 14556925 ↗ Nov 2003